ロード中...
Salvage camrelizumab plus apatinib for relapsed esophageal neuroendocrine carcinoma after esophagectomy: a case report and review of the literature
The current evidence regarding immunotherapy plus targeted therapy in esophageal neuroendocrine carcinoma (NEC) is lacking. Camrelizumab is a programmed cell death protein 1 inhibitor. Apatinib is a selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2. A 50-year-old f...
保存先:
| 出版年: | Cancer Biol Ther |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Taylor & Francis
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7678944/ https://ncbi.nlm.nih.gov/pubmed/33092443 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2020.1829265 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|